SCHEMBL5127019

SCHEMBL5127019

CN(c1ccccc1C(=O)O)S(=O)(=O)C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 3/20 0.43
KDM4E B2RXH2 5/20 0.43
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 5/20 0.41
ALOX15 P16050 2/20 0.41
GAA P10253 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 2/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5122954 0.98 KMT2A (0.44) KMT2ATDP1KDM4EPOLBL3MBTL1
SCHEMBL3351370 0.86 KMT2A (0.44) KMT2AKDM4EPOLBL3MBTL1HSD17B10
SCHEMBL11340781 0.81 ALDH1A1 (0.41) KMT2ATDP1KDM4EPOLBMAPT
SCHEMBL30005605 0.80 KMT2A (0.68) KMT2ATDP1POLBL3MBTL1HSD17B10
SCHEMBL222373 0.80 KMT2A (0.68) KMT2ATDP1POLBL3MBTL1HSD17B10
SCHEMBL22638587 0.78 KMT2A (0.49) KMT2ATDP1KDM4EPOLBL3MBTL1
SCHEMBL9888504 0.73 NR1H3 (0.49) KMT2AKDM4EALDH1A1CA12CA2
SCHEMBL18158039 0.73 ALDH1A1 (0.56) TDP1KDM4EPOLBESR1HSD17B10
SCHEMBL15240 0.73 ALDH1A1 (0.72) TDP1KDM4EPOLBMAPTLMNA
SCHEMBL11291472 0.72 ALDH1A1 (0.38) KMT2AKDM4EMAPTALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 KMT2A 2573/4885TDP1 332/4885KDM4E 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.